Cipla Limited — Important, 13-05-2025: General Updates

Cipla has announced a board meeting to discuss the financial results for the quarter and half-year. Q4 revenue grew 9% to INR 6,730 Cr with EBITDA margin at 22.8% and PAT up 30%. FY25 revenues rose 8.2% to INR 27,548 Cr, PAT up 28.4% to INR 5,273 Cr. Strong growth across India, North America, and Africa. Key brand Foracort crossed INR 900 Cr in revenue. Recent approvals for Nilotinib and Nano Paclitaxel, plus strategic alliances, support pipeline growth. Net cash exceeds $1 billion, backing expansion plans.